PMID- 37233879
OWN - NLM
STAT- MEDLINE
DCOM- 20231221
LR  - 20240409
IS  - 1591-9528 (Electronic)
IS  - 1591-8890 (Print)
IS  - 1591-8890 (Linking)
VI  - 23
IP  - 8
DP  - 2023 Dec
TI  - Immune-related lncRNAs pairs prognostic score model for prediction of survival in 
      acute myeloid leukemia patients.
PG  - 4527-4538
LID - 10.1007/s10238-023-01085-2 [doi]
AB  - Acute myeloid leukemia (AML) is one of the most common malignant and aggressive 
      hematologic tumors, and risk stratification is indispensable to ensure proper 
      treatment. But immune-related long noncoding RNAs (ir-lncRNAs) pairs prognostic 
      risk models used to stratify AML have yet to be reported. In this study, we 
      established a prognostic risk model based on eight ir-lncRNAs pairs using 
      LASSO-penalized Cox regression analysis and successfully validated the model in 
      an independent cohort. According to risk scores, patients were divided into a 
      high-risk group and a low-risk group. High-risk patients presented more tumor 
      mutation frequency and higher expression of human leukocyte antigen (HLA)-related 
      genes and immune checkpoint molecules. Gene Set Enrichment Analysis (GSEA) 
      indicated that the transforming growth factors beta (TGFbeta) pathway was activated in 
      the high-risk group; meanwhile, we found that TGFbeta1 mRNA levels were 
      significantly elevated in AML patients and correlated with poor prognosis, which 
      is closely related to drug resistance. Consistently, in vitro studies found that 
      exogenous TGFbeta1 can protect AML cells from chemotherapy-induced apoptosis. 
      Collectively, we developed an ir-lncRNA prognostic model that helps predict the 
      prognosis of AML patients and provides valuable information about their response 
      to immune checkpoint inhibitors, and we found that increased TGFbeta1 levels 
      resulting in chemoresistance may be one of the leading causes of treatment 
      failure in high-risk AML patients.
CI  - (c) 2023. The Author(s).
FAU - Liang, Xue
AU  - Liang X
AD  - Department of Hematology/Hematological Lab, The Second Affiliated Hospital of 
      Anhui Medical University, Hefei, Anhui, China.
FAU - Li, Cong
AU  - Li C
AD  - Department of Hematology/Hematological Lab, The Second Affiliated Hospital of 
      Anhui Medical University, Hefei, Anhui, China.
FAU - Fan, Mengmeng
AU  - Fan M
AD  - Department of Hematology/Hematological Lab, The Second Affiliated Hospital of 
      Anhui Medical University, Hefei, Anhui, China.
FAU - Zhang, Wanqiu
AU  - Zhang W
AD  - Department of Hematology/Hematological Lab, The Second Affiliated Hospital of 
      Anhui Medical University, Hefei, Anhui, China.
FAU - Liu, Linlin
AU  - Liu L
AD  - Department of Hematology/Hematological Lab, The Second Affiliated Hospital of 
      Anhui Medical University, Hefei, Anhui, China.
FAU - Zhou, Ji
AU  - Zhou J
AD  - Department of Hematology/Hematological Lab, The Second Affiliated Hospital of 
      Anhui Medical University, Hefei, Anhui, China.
FAU - Hu, Linhui
AU  - Hu L
AD  - Department of Hematology/Hematological Lab, The Second Affiliated Hospital of 
      Anhui Medical University, Hefei, Anhui, China.
FAU - Zhai, Zhimin
AU  - Zhai Z
AD  - Department of Hematology/Hematological Lab, The Second Affiliated Hospital of 
      Anhui Medical University, Hefei, Anhui, China. zzzm889@163.com.
LA  - eng
GR  - 201903a07020030/the major subject of science and technology of Anhui province/
PT  - Journal Article
DEP - 20230526
PL  - Italy
TA  - Clin Exp Med
JT  - Clinical and experimental medicine
JID - 100973405
RN  - 0 (RNA, Long Noncoding)
SB  - IM
MH  - Humans
MH  - Prognosis
MH  - *RNA, Long Noncoding/genetics
MH  - *Leukemia, Myeloid, Acute/drug therapy/genetics/pathology
MH  - Risk Factors
MH  - Research Design
PMC - PMC10725353
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - Chemoresistance
OT  - Prognostic model
OT  - TGFbeta
OT  - lncRNAs
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/05/26 13:09
MHDA- 2023/12/21 06:42
PMCR- 2023/05/26
CRDT- 2023/05/26 11:10
PHST- 2022/11/30 00:00 [received]
PHST- 2023/04/28 00:00 [accepted]
PHST- 2023/12/21 06:42 [medline]
PHST- 2023/05/26 13:09 [pubmed]
PHST- 2023/05/26 11:10 [entrez]
PHST- 2023/05/26 00:00 [pmc-release]
AID - 10.1007/s10238-023-01085-2 [pii]
AID - 1085 [pii]
AID - 10.1007/s10238-023-01085-2 [doi]
PST - ppublish
SO  - Clin Exp Med. 2023 Dec;23(8):4527-4538. doi: 10.1007/s10238-023-01085-2. Epub 
      2023 May 26.